23062-52-4

Basic information

• Product Name: Bicyclo[2.2.2]octane-1-carboxylic acid, 4-phenyl-, methyl ester
• Synonyms: 4-Phenyl-1-methoxycarbonyl-bicyclo<2.2.2>octan;1-Methoxycarbonyl-4-Phenylbicyclo
• CAS NO: 23062-52-4
• Molecular Formula: C16H20O2
• Molecular Weight: 244.334
• Mol File: 23062-52-4.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: Bicyclo[2.2.2]octane-1-carboxylic acid, 4-phenyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Bicyclo[2.2.2]octane-1-carboxylic acid, 4-phenyl-, methyl ester(23062-52-4)
• EPA Substance Registry System: Bicyclo[2.2.2]octane-1-carboxylic acid, 4-phenyl-, methyl ester(23062-52-4)

Safety Data

• Hazardous Substances Data: 23062-52-4(Hazardous Substances Data)

Upstream product

• 94-60-0 dimethyl 1,4-cyclohexane dicarboxylate 
• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 
• 38111-44-3 phenylzinc(II) bromide 
• 100-58-3 phenylmagnesium bromide 
• 1078-58-6 diphenylzinc 
• 1659-96-7 1,4-dibromo-trans-cyclohexane-1,4-dicarboxylic acid dimethyl ester 
• 1459-96-7 dimethyl bicyclo[2.2.2]octane-1,4-dicarboxylate 
• 100-21-0 terephthalic acid 
• 1659-67-2 dimethyl bicyclo[2.2.2]oct-2-ene-1,4-dicarboxylate 
• 1659-95-6 dimethyl 1,3-cyclohexadiene-1,4-dicarboxylate 
• 23062-51-3 methyl 4-bromo-bicyclo[2.2.2]octane-1-carboxylate 
• 71-43-2 benzene 

Downstream Products

• 18720-35-9 bicyclo[2.2.2]octane-1,4-dicarboxylic acid monomethyl ester 
• 1246852-75-4 methyl 4-(4-bromophenyl)bicyclo[2.2.2]octane-1-carboxylate 
• 94994-29-3 4-phenylbicyclo<2.2.2>octane-1-carboxaldehyde 
• 23760-80-7 4-phenylbicyclo<2.2.2>octane-1-methanol 
• 1246852-78-7 C₂₆H₃₅BrN₂O₄ 
• 1246852-77-6 2-amino-1-(4-(4-bromophenyl)bicyclo[2.2.2]octan-1-yl)ethanone hydrochloride 
• 1246852-76-5 1-(4-(4-bromophenyl)bicyclo[2.2.2]octan1-yl)-2-chloroethanone 
• 1228669-17-7 C₄₂H₅₈N₈O₆ 

Relevant articles and documents

Structure-Activity Relationship of para-Carborane Selective Estrogen Receptor β Agonists

Selective agonism of the estrogen receptor (ER) subtypes, ERα and ERβ, has historically been difficult to achieve due to the high degree of ligand-binding domain structural similarity. Multiple efforts have focused on the use of classical organic scaffold

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R2, R3a, R3b, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.